sorafenib + carboplatin + paclitaxel + bevacizumab

This is a combination regimen consisting of four oncology drugs: **sorafenib** (an oral multi-kinase inhibitor), **carboplatin** (a platinum-based chemotherapy), **paclitaxel** (a microtubule inhibitor), and **bevacizumab** (a monoclonal antibody targeting vascular endothelial growth factor A). The regimen is being explored in advanced solid tumors such as non-small cell lung cancer (NSCLC), melanoma, ovarian cancer, and head and neck squamous cell carcinoma, typically in metastatic or recurrent settings. - **Sorafenib** inhibits multiple intracellular and cell surface kinases associated with tumor cell proliferation and angiogenesis, specifically targeting RAF kinases, VEGF receptors 1/2/3, and PDGF receptor beta. - **Carboplatin** exerts its cytotoxic effect by forming DNA crosslinks, inhibiting DNA synthesis. - **Paclitaxel** stabilizes microtubules and prevents their depolymerization, arresting the cell cycle. - **Bevacizumab** is a monoclonal antibody that binds and neutralizes VEGF-A, thereby inhibiting angiogenesis necessary for tumor growth. The combination is **investigational**; it has been evaluated in phase I and II trials for tolerability, pharmacokinetics, pharmacogenomics, and efficacy, often in patients who have failed first-line therapies or have advanced/recurrent tumors[2][4][5][6][8]. Trials suggest that while the regimen has shown activity, especially in ovarian and other solid tumors, toxicity (notably overlapping anti-angiogenic side effects and myelosuppression) can be significant and may require dose modifications[4][6][8]. There is no established brand or trade name for this four-drug combination.